{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T17:51:56Z","timestamp":1789581116784,"version":"build-2803163510"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:00:00Z","timestamp":1780617600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Microbiol."],"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>This study aimed to explore the sex-specific regulatory effects of empagliflozin on gut microbiota in male and female diabetic kidney disease (DKD) mice, and to elucidate the underlying renoprotective mechanisms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Four-week-old db\/db mice and C57 mice were randomly assigned to six groups. Following 8 weeks of empagliflozin gavage, serum metabolic indices and urinary albumin-to-creatinine ratio (ACR) were measured. Renal pathological alterations were evaluated via hematoxylin-eosin and Masson\u2019s trichrome staining. Gut microbiota diversity and community composition were analyzed using 16S rRNA gene sequencing, and Spearman\u2019s rank correlation analysis was performed to assess associations between dominant microbial taxa and metabolic\/renal parameters.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      ACR levels were significantly elevated in db\/db mice compared to sex-matched C57 controls, with male db\/db mice exhibiting significantly higher ACR than females. Empagliflozin significantly reduced ACR in db\/db mice, albeit ACR remained significantly higher in males than females post-treatment. Meanwhile, empagliflozin ameliorated glomerular hypertrophy and mesangial proliferation. Pronounced sexual differences were observed in gut microbiota diversity of db\/db mice, with female mice displaying significantly higher microbial richness than males. Empagliflozin effectively reshaped gut microbiota composition and alleviated microbial dysbiosis in db\/db mice, with these regulatory effects showing distinct sex specificity. Furthermore, several dominant microbial taxa (e.g.,\n                      <jats:italic>Rikenellaceae_RC9_gut_group<\/jats:italic>\n                      ,\n                      <jats:italic>Parabacteroides<\/jats:italic>\n                      ,\n                      <jats:italic>Klebsiella<\/jats:italic>\n                      ) were identified to be significantly correlated with ACR, and these correlations were sex-dependent.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Empagliflozin significantly reduces ACR levels and modulates gut microbial richness and diversity in db\/db mice, with distinct sex-specific effects on microbiota composition. Ultimately, these findings suggest that empagliflozin may exert renoprotective effects in DKD by reshaping gut microbial community structure.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmicb.2026.1790953","type":"journal-article","created":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T05:07:18Z","timestamp":1780636038000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Sex-specific modulation of gut microbiota by empagliflozin contributes to renoprotection in diabetic kidney disease mice"],"prefix":"10.3389","volume":"17","author":[{"given":"Jundong","family":"He","sequence":"first","affiliation":[{"name":"Department of Endocrinology and Metabolism, The First People\u2019s Hospital of Yunnan Province, The Affiliated Hospital of Kunming University of Science and Technology, Kunming","place":["Yunnan, China"]},{"name":"School of Medicine, Kunming University of Science and Technology, Kunming","place":["Yunnan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxin","family":"Liu","sequence":"additional","affiliation":[{"name":"School of Medicine, Kunming University of Science and Technology, Kunming","place":["Yunnan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heming","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, The First People\u2019s Hospital of Yunnan Province, The Affiliated Hospital of Kunming University of Science and Technology, Kunming","place":["Yunnan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiting","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, The First People\u2019s Hospital of Yunnan Province, The Affiliated Hospital of Kunming University of Science and Technology, Kunming","place":["Yunnan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1161\/circulationaha.123.065517","article-title":"Metabolic communication by SGLT2 inhibition.","volume":"149","author":"Billing","year":"2024","journal-title":"Circulation"},{"key":"B2","doi-asserted-by":"publisher","first-page":"159234","DOI":"10.1016\/j.bbalip.2022.159234","article-title":"Empagliflozin ameliorates type 2 diabetes mellitus-related diabetic nephropathy via altering the gut microbiota.","volume":"1867","author":"Deng","year":"2022","journal-title":"Biochim. Biophys. Acta Mol. Cell Biol. Lipids"},{"key":"B3","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1124\/jpet.118.248575","article-title":"Potent Sodium\/Glucose cotransporter SGLT1\/2 dual inhibition improves glycemic control without marked gastrointestinal adaptation or colonic microbiota changes in rodents.","volume":"365","author":"Du","year":"2018","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B4","doi-asserted-by":"publisher","first-page":"e55149","DOI":"10.7759\/cureus.55149","article-title":"Exploring the impact of optimized probiotic supplementation techniques on diabetic nephropathy: Mechanisms and therapeutic potential.","volume":"16","author":"Ghosh","year":"2024","journal-title":"Cureus"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1018093","DOI":"10.3389\/fendo.2022.1018093","article-title":"A systematic review and meta-analysis of gut microbiota in diabetic kidney disease: Comparisons with diabetes mellitus, non-diabetic kidney disease, and healthy individuals.","volume":"13","author":"Han","year":"2022","journal-title":"Front. Endocrinol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"755","DOI":"10.2147\/dmso.S347805","article-title":"Compositional alterations of gut microbiota in patients with diabetic kidney disease and Type 2 diabetes mellitus.","volume":"15","author":"He","year":"2022","journal-title":"Diab. Metab. Syndr. Obes."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1053900","DOI":"10.3389\/fendo.2022.1053900","article-title":"Specific alterations of gut microbiota in diabetic microvascular complications: A systematic review and meta-analysis.","volume":"13","author":"Hong","year":"2022","journal-title":"Front. Endocrinol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1602594","DOI":"10.3389\/fendo.2025.1602594","article-title":"Immune inflammation and metabolic interactions in the pathogenesis of diabetic nephropathy.","volume":"16","author":"Hou","year":"2025","journal-title":"Front. Endocrinol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"12179","DOI":"10.1038\/s41598-025-91281-9","article-title":"Predicting diabetic kidney disease with serum metabolomics and gut microbiota.","volume":"15","author":"Hu","year":"2025","journal-title":"Sci. Rep."},{"key":"B10","doi-asserted-by":"publisher","first-page":"181","DOI":"10.4093\/dmj.2021.0329","article-title":"Pathophysiologic mechanisms and potential biomarkers in diabetic kidney disease.","volume":"46","author":"Jung","year":"2022","journal-title":"Diab. Metab. J."},{"key":"B11","doi-asserted-by":"publisher","first-page":"4626382","DOI":"10.1155\/2016\/4626382","article-title":"Sex differences in the renal function decline of patients with Type 2 diabetes.","volume":"2016","author":"Kajiwara","year":"2016","journal-title":"J. Diab. Res."},{"key":"B12","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1097\/mnh.0000000000000561","article-title":"Renoprotective effects of sodium-glucose cotransporter-2 inhibitors and underlying mechanisms.","volume":"29","author":"Kashihara","year":"2020","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"B13","doi-asserted-by":"publisher","first-page":"11456","DOI":"10.3390\/ijms241411456","article-title":"Gut microbiome and microbiome-derived metabolites in patients with end-stage kidney disease.","volume":"24","author":"Koshida","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"B14","doi-asserted-by":"publisher","first-page":"154935","DOI":"10.1016\/j.phymed.2023.154935","article-title":"FTZ polysaccharides ameliorate kidney injury in diabetic mice by regulating gut-kidney axis.","volume":"118","author":"Lan","year":"2023","journal-title":"Phytomedicine"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1182570","DOI":"10.3389\/fcell.2023.1182570","article-title":"Short-chain fatty acids directly exert anti-inflammatory responses in podocytes and tubular epithelial cells exposed to high glucose.","volume":"11","author":"Li","year":"2023","journal-title":"Front. Cell Dev. Biol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1681\/asn.2021060843","article-title":"Intestinal bacterial translocation contributes to diabetic kidney disease.","volume":"33","author":"Linh","year":"2022","journal-title":"J. Am. Soc. Nephrol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1038\/s41401-019-0326-5","article-title":"Gut microbiota dysbiosis-induced activation of the intrarenal renin-angiotensin system is involved in kidney injuries in rat diabetic nephropathy.","volume":"41","author":"Lu","year":"2020","journal-title":"Acta Pharmacol. Sin"},{"key":"B18","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.mayocp.2019.08.026","article-title":"Sex differences in diabetic kidney disease.","volume":"95","author":"Maric-Bilkan","year":"2020","journal-title":"Mayo Clin. Proc."},{"key":"B19","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41574-025-01171-3","article-title":"Mechanisms of diabetic kidney disease and established and emerging treatments.","volume":"22","author":"Martinez Leon","year":"2026","journal-title":"Nat. Rev. Endocrinol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/s41581-024-00836-y","article-title":"Applications of SGLT2 inhibitors beyond glycaemic control.","volume":"20","author":"O\u2019Hara","year":"2024","journal-title":"Nat. Rev. Nephrol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"723","DOI":"10.3390\/biology14060723","article-title":"Gut microbiome engineering for diabetic kidney disease prevention: A Lactobacillus rhamnosus GG intervention study.","volume":"14","author":"Qumsani","year":"2025","journal-title":"Biology"},{"key":"B22","doi-asserted-by":"publisher","first-page":"964389","DOI":"10.3389\/fendo.2022.964389","article-title":"The harmful intestinal microbial community accumulates during DKD exacerbation and microbiome-metabolome combined validation in a mouse model.","volume":"13","author":"Shang","year":"2022","journal-title":"Front. Endocrinol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"2270061","DOI":"10.1080\/0886022x.2023.2270061","article-title":"The intellectual base and global trends in inflammation of diabetic kidney disease: A bibliometric analysis.","volume":"45","author":"Shi","year":"2023","journal-title":"Ren. Fail"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.3390\/microorganisms8091347","article-title":"Gut microbial changes in diabetic db\/db mice and recovery of microbial diversity upon pirfenidone treatment.","volume":"8","author":"Singh","year":"2020","journal-title":"Microorganisms"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1034818","DOI":"10.3389\/fendo.2022.1034818","article-title":"Sacubitril\/Valsartan contributes to improving the diabetic kidney disease and regulating the gut microbiota in mice.","volume":"13","author":"Wang","year":"2022","journal-title":"Front. Endocrinol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"2566381","DOI":"10.1080\/0886022x.2025.2566381","article-title":"Causal effects of gut microbiota on diabetic kidney disease: Insights from 16S rRNA sequencing and bidirectional Mendelian randomization.","volume":"47","author":"Wang","year":"2025","journal-title":"Ren. Fail"},{"key":"B27","doi-asserted-by":"publisher","first-page":"670674","DOI":"10.3389\/fendo.2021.670674","article-title":"Sex differences in biopsy-confirmed diabetic kidney disease.","volume":"12","author":"Wang","year":"2021","journal-title":"Front. Endocrinol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"908219","DOI":"10.3389\/fimmu.2022.908219","article-title":"The specific alteration of gut microbiota in diabetic kidney diseases-a systematic review and meta-analysis.","volume":"13","author":"Wang","year":"2022","journal-title":"Front. Immunol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"855","DOI":"10.3389\/fendo.2019.00855","article-title":"Implications of a family history of diabetes and rapid eGFR decline in patients with Type 2 diabetes and biopsy-proven diabetic kidney disease.","volume":"10","author":"Wang","year":"2019","journal-title":"Front. Endocrinol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1026040","DOI":"10.3389\/fendo.2023.1026040","article-title":"Sodium glucose co-transporter 2 (SGLT2) inhibition via dapagliflozin improves diabetic kidney disease (DKD) over time associatied with increasing effect on the gut microbiota in db\/db mice.","volume":"14","author":"Wu","year":"2023","journal-title":"Front. Endocrinol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1441415","DOI":"10.3389\/fendo.2024.1441415","article-title":"Intestinal flora and bile acid interactions impact the progression of diabetic kidney disease.","volume":"15","author":"Xu","year":"2024","journal-title":"Front. Endocrinol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"e42492","DOI":"10.1097\/md.0000000000042492","article-title":"Gut microbiome and diabetic kidney disease: Insights from Mendelian randomization and genetic correlations.","volume":"104","author":"Yang","year":"2025","journal-title":"Medicine"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.7754\/Clin.Lab.2021.210836","article-title":"Serum trimethylamine N-oxide and the diversity of the intestinal microbial flora in Type 2 diabetes complicated by diabetic kidney disease.","volume":"68","author":"Yang","year":"2022","journal-title":"Clin. Lab."},{"key":"B34","doi-asserted-by":"publisher","first-page":"176905","DOI":"10.1016\/j.ejphar.2024.176905","article-title":"Liraglutide ameliorates diabetic kidney disease by modulating gut microbiota and L-5-Oxoproline.","volume":"983","author":"Yi","year":"2024","journal-title":"Eur. J. Pharmacol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s40200-025-01579-8","article-title":"Alterations of the gut microbiota in patients with diabetic nephropathy and its association with the renin-angiotensin system.","volume":"24","author":"Zali","year":"2025","journal-title":"J. Diab. Metab. Disord."},{"key":"B36","doi-asserted-by":"publisher","first-page":"e0038223","DOI":"10.1128\/spectrum.00382-23","article-title":"The intestinal microbiota composition in early and late stages of diabetic kidney disease.","volume":"11","author":"Zhang","year":"2023","journal-title":"Microbiol. Spectr."}],"container-title":["Frontiers in Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2026.1790953\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T05:07:19Z","timestamp":1780636039000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2026.1790953\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,5]]},"references-count":36,"alternative-id":["10.3389\/fmicb.2026.1790953"],"URL":"https:\/\/doi.org\/10.3389\/fmicb.2026.1790953","relation":{},"ISSN":["1664-302X"],"issn-type":[{"value":"1664-302X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,5]]},"article-number":"1790953"}}